Tag: Espero

Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial Fibrillation

JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin […]

Espero BioPharma Provides Update on the Development of Tecarfarin for the Treatment of Mechanical Heart Valve Patients in China

JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis and cardiac rhythm control, today announced that Lee’s Pharmaceutical Holdings Limited and its subsidiaries (collectively “Lee’s Pharmaceutical”) has completed its Phase […]

Espero BioPharma to Present at the 2018 BIO International Convention, Wednesday, June 6, 2018

JACKSONVILLE, Fla., May 30, 2018 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Quang Pham, Espero’s Chief Executive Officer, will present at the 2018 BIO International Convention at 2:00 PM ET […]